Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1Recruiting 1Not yet recruiting 1Enrolling by invitation 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Neoplasms 40Breast Neoplasms 38Prostatic Neoplasms 24Colorectal Neoplasms 23Uterine Cervical Neoplasms 16Carcinoma, Non-Small-Cell Lung 13Anxiety Disorders 13Stomach Neoplasms 9Lymphoma, Follicular 9Leukemia, Myeloid, Acute 9Carcinoma, Hepatocellular 9Brain Neoplasms 9Lung Neoplasms 8Head and Neck Neoplasms 8Urinary Bladder Neoplasms 7Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Esophageal Neoplasms 7Sarcoma 6Ovarian Neoplasms 6Esophageal Squamous Cell Carcinoma 6Depression 6Colonic Neoplasms 6Uterine Cervical Dysplasia 5Small Cell Lung Carcinoma 5Pain 5Glioma 5Epilepsy 5Dementia 5Cholangiocarcinoma 5Squamous Cell Carcinoma of Head and Neck 4

Interventions

ribociclib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Enrolling by invitation × Interventional × HER2-positive Advanced Breast Cancer × Clear all
NCT06481956 2024-07-01

T-DM1 Combined With CDK4/6 Inhibitor Ribociclib

Zhejiang Cancer Hospital

Phase 2 Enrolling by invitation
40 enrolled
Breast

HER2-positive Advanced Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡